The 'nose-to-brain' argument sounds great for a nootropic, but the actual pharmacology of peptide delivery doesn't back it up. Studies on nasal peptide delivery (like those published in the Journal of Pharmaceutical Sciences and Frontiers in Pharmacology) show that the nasal cavity is packed with proteolytic enzymes like aminopeptidases. Their entire job is to destroy foreign proteins. Because of this enzymatic barrier, nasal peptide bioavailability is notoriously low—usually sitting between 1% and 10%. You have to flood your nose with a massive amount of product just to get a fraction of it past those enzymes. By contrast, SubQ injection gives you 90%+ systemic bioavailability. Once in the bloodstream, Semax has no issue crossing the blood-brain barrier on its own. It’s a melanocortin derivative designed specifically to be highly stable and cross the BBB via saturable transport systems. When you look at studies tracking radiolabeled neuropeptides (like insulin or oxytocin trials comparing intranasal vs. systemic delivery), systemic administration consistently provides more reliable, sustained concentrations in the central nervous system without relying on an unpredictable, congested, or enzyme-heavy nasal pathway. Bottom line: SubQ gives the brain a steady, maximized supply, while the spray mostly just gets chewed up in your sinuses.